Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.